Pharmacokinetic Evidence of Steady and Sustained Drug Release from Long-Acting Implantable Corticosteroid Matrices for Chronic Rhinosinusitis.
| Autor: | Ow RA; Sacramento Ear, Nose, and Throat, Roseville, California., Shotts S; Advanced ENT and Allergy, Louisville, Kentucky., Kakarlapudi V; Advanced ENT and Allergy, New Albany, Indiana., McIntyre J; Fort Worth ENT, Fort Worth, Texas., Naclerio RM; 310950Johns Hopkins University, Baltimore, Maryland., You C; Lyra Therapeutics, Inc., Watertown, Massachusetts., Pappas A; Lyra Therapeutics, Inc., Watertown, Massachusetts., Brayton L; Lyra Therapeutics, Inc., Watertown, Massachusetts., Kuang Y; Lyra Therapeutics, Inc., Watertown, Massachusetts., Shao J; Lyra Therapeutics, Inc., Watertown, Massachusetts. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | American journal of rhinology & allergy [Am J Rhinol Allergy] 2022 Nov; Vol. 36 (6), pp. 733-740. Date of Electronic Publication: 2022 Jun 16. |
| DOI: | 10.1177/19458924221107200 |
| Abstrakt: | Background: The efficacy of topical corticosteroids is limited in chronic rhinosinusitis (CRS) due to rapid clearance from the nasal cavity and insufficient drug delivery to inflamed sinonasal passages. LYR-210 is an implantable corticosteroid matrix designed to provide up to 24 weeks of treatment to patients with CRS by locally delivering mometasone furoate (MF) to the sinonasal mucosa. In a randomized, controlled, dose-ranging LANTERN study, LYR-210 (7500 µg) achieved clinically relevant improvement in CRS cardinal symptom composite scores, the 22-item Sinonasal Outcome Test (SNOT-22), ethmoid opacification, and the need for rescue treatment at 24 weeks. Objective: As the plasma MF concentrations of LYR-210 (2500 µg) and LYR-210 (7500 µg) were evaluated at weeks 4, 12, and 24 in the LANTERN study (data on file at Lyra Therapeutics, Inc.), this study aims to characterize the pharmacokinetic profiles of both doses of LYR-210 at earlier timepoints post-placement in patients with CRS. Methods: Twenty-four surgically naïve adult patients with CRS were enrolled in an open-label, multicenter study and underwent in-office bilateral administration of LYR-210 (2500 µg) ( n = 12 patients) or LYR-210 (7500 µg) ( n = 12 patients) into the middle meatus. Plasma MF concentrations were determined pre-placement and 1-h post-placement (day 1), and on days 2, 3, 7, 14, 21, 28, 42, and 56 by liquid chromatography-tandem mass spectrometry. Results: Both LYR-210 doses were well-tolerated with no serious adverse events. Systemic MF levels were dose-dependent and lower than reported values of other respiratory MF products. Plasma MF concentrations showed steady drug release from LYR-210 (2500 µg) and LYR-210 (7500 µg) that persisted through day 56. Conclusion: LYR-210 achieved dose-dependent, continuous local MF delivery at a steady rate with low systemic exposure for months. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|